Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. (Q46748085)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. |
scientific article |
Statements
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group (English)
Jon Richards
Eric Whitman
Jose Lutzky
Giorgio Parmiani
Giulio Tosti
John M Kirkwood
Axel Hoos
Lianng Yuh
Renu Gupta
Pramod K Srivastava
C-100-21 Study Group